APVO: Aptevo Therapeutics, Inc. Price to Sales
Aptevo Therapeutics (APVO) is expanding its presence in the immuno-oncology segment by implementing bispecific antibodies via the ADAPTIR system. The price-to-sales ratio illustrates the business valuation trend, where the latest parameter stands at 2.90. The company's operations rely on external investments and grants due to a lack of profitability. Critically low liquidity combined with the complexity of clinical trials creates significant operational threats.
Analytical breakdowns for Aptevo Therapeutics (APVO)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Aggregate Debt to Capital Aptevo Therapeutics|APVO - Long-Term Debt to Capital|Current Liabilities to Capital aptevotherapeutics.com|APVO - Company Total Debt|Debt to Book Capitalization Ratio Aptevo|APVO - Company Long-Term Debt|Short-Term Debt Aptevo Therapeutics|Intermediate Coverage Ratio aptevotherapeutics.com
- company profitability and valuation multiples indicators:
APVO - Net Income|Future Net Profit Aptevo Therapeutics|APVO - P/E Multiple|Future Price to Earnings Multiple aptevotherapeutics.com|APVO - PEG Multiple|Company Value to EBITDA Aptevo|APVO - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Aptevo Therapeutics|APVO - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth aptevotherapeutics.com|APVO - Earnings per share growth in current year|Net earnings per share change forecast for next year Aptevo Therapeutics
- total revenue and sales volume data:
Summary company analytics:Aptevo Therapeutics, Inc. APVO
To balance capital risks and returns in biotech, Aptevo Therapeutics (APVO) finds the assessment of market value relative to actual sales critically important. By analyzing the P/S trajectory, an investor determines the extent to which the market overvalues the potential of the ADAPTIR platform in the cancer immunotherapy segment, comparing market capitalization with current revenue to confirm the fundamental stability of the business.
Competitors of Aptevo Therapeutics
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|PTGX - P/S Multiple|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|Price-to-Sales Ratio KNSA (kiniksa.com)|Market Cap to Revenue GRFS|ADPT (Adaptive Biotech) - Market Cap to Sales Volume|P/S Multiple CLDX|AUPH - Price to Sales|BioCryst - Market Cap to Revenue|veratx.com - Price-to-Revenue Ratio|DNTH - Price-to-Revenue Ratio|Price to Sales Pharvaris NV|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|Tourmaline - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue PGEN|PHAR (pharming.com) - Market Cap to Sales Volume|P/S Multiple NKTR|UPB (Upstream Bio, Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Immunome Bio (IMNM) - Price to Sales|GOSS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio KALV (kalvista.com)|SEPN: P/S Multiple|Pieris Pharma (PVLA) - P/S Multiple|Price-to-Revenue Ratio Savara Corp|Rigel Corp - Price-to-Sales Ratio|P/S Multiple ANAB|ATXS - Price to Sales|enGene - Market Cap to Revenue|P/S Multiple RAPT Therapeutics Inc. RAPT|JBIO: Market Cap to Revenue|Aclaris Therapeutics, Inc - Market Cap to Sales Volume|KYTX: P/S Multiple|TLSA - Price-to-Revenue Coefficient|CABA (Cabaletta Bio) - P/S Multiple|Market Cap to Revenue Ventyx Biosciences Inc. (VTYX)|Price-to-Revenue Ratio Theratechnologies Inc (THTX)|Price-to-Revenue Coefficient Avalo Therapeutics Inc|P/S Multiple ELDN (Eledon Pharmaceuticals)|P/S Multiple agenusbio.com AGEN|CLYM - Price-to-Revenue Ratio|Price-to-Sales Ratio ZURA|ATYR (aTyr) - Market Cap to Revenue|ADAG (Adagene Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio ImageneBio|Price to Sales Shattuck Therapeutics STTK|Price-to-Revenue Ratio Equillium, Inc. (EQ)|CNTB: Price-to-Sales Ratio|P/S Multiple IMUX (Immunic)|Market Capitalization-to-Revenue Ratio ATRA|InflaRx GmbH - P/S Multiple|XFOR - P/S Multiple|adicetbio.com (ACET) - Price-to-Revenue Ratio|Celularity - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio INmune Bio Corp|Market Cap to Revenue Barinthus Biotherapeutics Corp (BRNS)|P/S Multiple KZR|P/S Multiple sabbiotherapeutics.com (SABS)|Akari Therapeutics Plc - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ENLV|Q32 Bio Corp - P/S Multiple|Price-to-Revenue Coefficient GeoVax Corp GOVX|Edesa Biotech, Inc. (EDSA) - Price-to-Revenue Ratio|Market Cap to Revenue ibioinc.com|Price-to-Revenue Ratio Carisma Therapeutics Inc|Market Cap to Revenue XTL Biopharmaceuticals Ltd (XTLB)|Market Cap to Revenue BOLT (Bolt Biotherapeutics)|P/S Multiple hcwbiologics.com (HCWB)|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX: Market Cap to Revenue Ratio|GRI Bio - P/S Multiple|Price to Sales XORTX Therapeutics Inc|HIND: P/S Multiple|Revelation Biosciences Corp (REVB) - P/S Multiple|Price-to-Revenue Ratio Indaptus Therapeutics|scinai.com - Price-to-Sales Ratio|Market Cap to Revenue CALI (CalciMedica, Inc.)|Market Cap to Sales Volume AFMD|P/S Multiple ALLK (Allakos)|HOOKIPA Pharma, Inc. (HOOK) - Price to Sales|IGMS: Market Cap to Revenue|ITOS: Price-to-Revenue Ratio|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|Price to Sales TC BioPharm (Holdings) Plc (TCBP)|Market Cap to Revenue THRD
